Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

European Stocks Slump; Virus Surge and SAP Warning Weigh

Published 26/10/2020, 08:39
Updated 26/10/2020, 08:41
© Reuters.

By Peter Nurse 

Investing.com - European stock markets traded sharply lower Monday, with surging coronavirus cases prompting more restrictive measures while software giant SAP offered up a profit warning.

SAP (DE:SAPG) stock slumped over 15% after the software giant cut its guidance for the year, abandoning its forecast that profitability would expand steadily over the medium term, saying coronavirus lockdowns would hit demand well into 2021. 

At 3:40 AM ET (0840 GMT), the DAX in Germany traded 2.4% lower, the CAC 40 in France fell 1%, while the U.K.'s FTSE index dropped 0.5%.

Europe has been hit hard by the second wave of the coronavirus, becoming the second region after Latin America to surpass 250,000 deaths on Saturday, according to a Reuters tally, as a number of countries reported a record number of cases.

Italy has responded by introducing the strongest virus restrictions since the end of a national lockdown in May, while Spain is set to impose a national curfew, having declared a national state of emergency at the weekend.

The news in the U.S. doesn’t make for good reading either. The country recorded the most infections of the pandemic for the second day in a row, adding another 85,317 cases, including aides of Vice President Mike Pence. Pence himself continues to attend election campaign rallies, while White House chief of staff Mark Meadows told CNN that "we aren't going to control the pandemic."

Elsewhere, Siemens (DE:SIEGn) stock fell 1.2% after Bloomberg reported that U.S. private equity firm Carlyle Group (NASDAQ:CG) is nearing an agreement to buy the German industrial giant’s mechanical drive arm Flender, for about 2 billion euros ($2.37 billion).

Bayer (DE:BAYGN) stock fell 0.2% after the German pharmaceutical giant agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion in a bet on gene therapy with the help of modified viruses.

Investors will keep a wary eye on the release of the German Ifo business climate indicator for October later in the session to see whether these rising Covid-19 numbers are having an impact on confidence in the country’s corporate sector.

Concerns about the virus also hit oil prices: U.S. crude futures traded 2.7% lower at $38.78 a barrel, while the international benchmark Brent contract fell 2.4% to $41.05. Brent fell 2.7% last week and WTI dropped 2.5%, their first weekly losses in three.

Oil traders will also be keeping an eye on the progress of tropical storm Zeta, which is poised to turn into a hurricane and disrupt oil production in the Gulf of Mexico.

Elsewhere, gold futures fell 0.3% to $1,899.20/oz, while EUR/USD traded 0.3% lower at 1.1818.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.